Celldex Therapeutics Inc (CLDX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $38.24 (-1.90%), Market cap $2.67B, 52-week low–high $18.66 ~ $34.55.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two
Financial statements, price targets, institutional (13F) holdings and related news for Celldex Therapeutics Inc are updated in real time on BlackAll Trade.
Celldex Therapeutics Inc trades at $38.24 (-1.90%). Real-time quotes and charts are available on BlackAll Trade.
Celldex Therapeutics Inc has a market cap of about $2.67B.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's dru